Abstracts tagged "methotrexate (MTX)"

Abstract Number: 446 • 2017 ACR/ARHP Annual Meeting
Methotrexate Use and Fatigue in Rheumatoid Arthritis Patients: Results from a National Patient Registry
Huifeng Yun¹, Shuo Yang², W. Benjamin Nowell³, Cooper Filby¹, Lang Chen¹ and Jeffrey R. Curtis⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Methotrexate (MTX), a synthetic disease-modifying antirheumatic drug (DMARD), is the most commonly used medication for rheumatoid arthritis (RA). Considerable variations between patients taking MTX…
Abstract Number: 2458 • 2017 ACR/ARHP Annual Meeting
Tocilizumab Inhibits Progression of Erosive Joint Damage in Early Rheumatoid Arthritis More Effectively Than Step-up Methotrexate Therapy
Xavier M Teitsma¹, Johannes WG Jacobs¹, Paco MJ Welsing², Attila Pethö-Schramm³, Michelle EA Borm⁴, Jacob M. van Laar⁵, Floris PJ Lafeber⁵ and Johannes W.J. Bijlsma², ¹Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³F. Hoffmann-La Roche, Basel, Switzerland, ⁴Beneluxlaan 2a, Roche Nederland BV, Woerden, Netherlands, ⁵Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: In early rheumatoid arthritis (RA), starting therapy as soon as possible is important to reduce disease activity and preserve the joints. With application of…
Abstract Number: 493 • 2017 ACR/ARHP Annual Meeting
Methotrexate Is an Antibacterial Drug Metabolized By Human Gut Bacteria
Renuka R. Nayak¹, Kye Stapleton-Gray², Colleen O'Loughlin³, Michael Fischbach⁴ and Peter J. Turnbaugh⁵, ¹Department of Medicine, Division of Rheumatology, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ²Carnegie Mellon University, Pittsburgh, PA, ³University of California, San Francisco, San Francisco, CA, ⁴Department of Bioengineering and Therapeutic Sciences,, University of California, San Francisco, San Francisco, CA, ⁵Microbiology and Immunology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease of unknown etiology causing inflammation and irreversible damage in joints and other organs. Methotrexate (MTX) is first-line…
Abstract Number: 2460 • 2017 ACR/ARHP Annual Meeting
Patient-Reported Outcomes Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: Results from a Randomized Controlled Trial
Joel Kremer¹, William F C Rigby², Nora Singer³, Christine Birchwood⁴, Darcy Gill⁴, William Reiss⁴, Jennie Best⁴, Jinglan Pei⁴ and Margaret Michalska⁴, ¹Albany Medical College, Albany, NY, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Case Western Reserve University School of Medicine, Cleveland, OH, ⁴Genentech, Inc., South San Francisco, CA
Background/Purpose: Patients with rheumatoid arthritis (RA) often receive methotrexate (MTX) in combination with biologics; however, MTX may be discontinued due to intolerance or to reduce…
Abstract Number: 615 • 2017 ACR/ARHP Annual Meeting
Efficacy of Tofacitinib By Background Methotrexate Dose in Patients with Psoriatic Arthritis: A Post Hoc Analysis of Pooled Data from 2 Phase 3 Trials
Alan J. Kivitz¹, Oliver FitzGerald², Peter Nash³, Shirley Pang⁴, Valderilio F Azevedo⁵, Elizabeth Kudlacz⁶, Cunshan Wang⁶, Daniela Graham⁶ and Liza Takiya⁷, ¹Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ²Department of Rheumatology, St Vincent's University Hospital, Dublin, Ireland, ³Department of Medicine, University of Queensland, St Lucia, Brisbane, Australia, ⁴St. Jude Medical Center, Fullerton, CA, ⁵Universidade Federal do Paraná, Curitiba, Brazil, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for psoriatic arthritis (PsA). The efficacy of tofacitinib has been evaluated in 2 Phase 3…
Abstract Number: 2465 • 2017 ACR/ARHP Annual Meeting
Association between Methotrexate Use and Effects of Treatment with a Second Biologic Agent in Rheumatoid Arthritis: A Multiple Imputation Approach
Yoshikazu Ogawa¹, Nobunori Takahashi², Naoki Ishiguro² and Toshihisa Kojima², ¹Sakashita Hospital, Nakatsugawa, Japan, ²Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose: Methotrexate (MTX) is recommended and widely prescribed as the first-line, evidence-based therapy for rheumatoid arthritis (RA) patients. Previous studies have demonstrated a significant effect…
Abstract Number: 804 • 2017 ACR/ARHP Annual Meeting
The Efficacy and Safety of the Anti-IL-6 Receptor Antibody Tocilizumab for Polymyalgia Rheumatica Patients with Resistance or Intolerance to Glucocorticoids and Methotrexate
Manami Hirata¹, Akiko Ueno², kazuyuki fujita², Nobuyuki Shibutou² and Masahiro Yamamura³, ¹Center for Rheumatology, Okayama Saiseikai General Hospital, Okayama, Japan, ²Centor for Rheumatology, Okayama Saiseikai General Hospital, Okayama, Japan, ³Okayama Saiseikai General Hospital, Okayama, Japan
Background/Purpose: Some patients show inadequate responses to initial glucocorticoids (GC) doses or relapses during GC tapering and develop side effects of GCs. The 2015 EULAR/ACR…
Abstract Number: 2962 • 2017 ACR/ARHP Annual Meeting
MRI Results Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: Results from a Randomized Controlled Trial
Charles Peterfy¹, Joel Kremer², William F C Rigby³, Nora Singer⁴, Christine Birchwood⁵, Darcy Gill⁵, William Reiss⁵, Jinglan Pei⁵ and Margaret Michalska⁵, ¹Spire Sciences, Inc., Boca Raton, FL, ²Albany Medical College, Albany, NY, ³Geisel School of Medicine at Dartmouth, Lebanon, NH, ⁴Case Western Reserve University School of Medicine, Cleveland, OH, ⁵Genentech, Inc., South San Francisco, CA
Background/Purpose: Although previous studies have established the efficacy of tocilizumab (TCZ) initiated as monotherapy (MONO) for the treatment of rheumatoid arthritis (RA),1,2 changes in active…
Abstract Number: 827 • 2017 ACR/ARHP Annual Meeting
Temporary Methotrexate Discontinuation for 2 Weeks Improves Immunogenicity of Seasonal Influenza Vaccination in Patients with Rheumatoid Arthritis: A Randomized Clinical Trial
Jin Kyun Park¹, Kichul Shin², You-Jung Ha³, Yun Jong Lee⁴, Eun Young Lee⁵, Yeong Wook Song⁶, Yunhee Choi⁷, Kevin Winthrop⁸ and Eun Bong Lee⁹, ¹Division of Rheumatology, Seoul National University Hospital, Seoul, Korea, Republic of (South), ²Kyungnam villa #102, Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of (South), ³Yonsei University College of Medicine, Seoul, Korea, Republic of (South), ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of (South), ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, Korea, Republic of (South), ⁶Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, Korea, The Republic of, Seoul, Korea, Republic of (South), ⁷Division of Medical Statistics, Medical Research Collaborating Center, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ⁸Oregon Health & Science University, Portland, OR, ⁹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South)
Background/Purpose: Methotrexate (MTX), a widely used immune-suppressive agent, decreases vaccine response in patients with rheumatoid arthritis (RA). We investigated whether a temporary MTX discontinuation for…
Abstract Number: 1252 • 2017 ACR/ARHP Annual Meeting
Real-World Oral Methotrexate Adherence Measured Electronically in Patients with Established Rheumatoid Arthritis
Kaleb Michaud^1,2, Rebecca Schumacher², Bernard Vrijens³, Eric Tousset³, Gorana Dasic⁴, Connie Chen⁴, Ekta Agarwal⁴ and Maria Suarez-Almazor⁵, ¹University of Nebraska Medical Center, Omaha, NE, ²National Data Bank for Rheumatic Diseases, Wichita, KS, ³WestRock Healthcare, Visé, Belgium, ⁴Pfizer Inc, New York, NY, ⁵Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX
Background/Purpose: While weekly methotrexate (MTX) remains the gold standard treatment for patients with RA, studies suggest that MTX adherence may be sub-optimal and could be…
Abstract Number: 1322 • 2017 ACR/ARHP Annual Meeting
Tissue Folate Dysregulation Is Associated with Disease Activity and Methotrexate Response in Collagen-Induced Arthritis
Leon van Haandel¹, Rakesh Singh², Paul Kiptoo³, Teruna Siahaan³, Mara L Becker⁴ and Ryan Funk⁵, ¹2401 Gillham Road, Children's Mercy, Kansas City, MO, ²Department of Pharmacy Practice, University of Kansas Medical Center, Kansas City, KS, ³Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, ⁴Rheumatology, Children's Mercy Kansas City, Kansas City, MO, ⁵University of Kansas Medical Center, Kansas City, KS
Background/Purpose: Methotrexate (MTX) is an anti-metabolite inhibitor of folate-dependent biochemical pathways and is effective in reducing disease activity in autoimmune arthritis. This work seeks to…
Abstract Number: 1399 • 2017 ACR/ARHP Annual Meeting
Tissues Are Differently Modulated By Tocilizumab and Methotrexate; Assessment of Connective Tissue Metabolites in the Ambition Study
Anne C. Bay-Jensen¹, Anne Sofie Siebuhr¹, Christian S. Thudium² and Morten Asser Karsdal¹, ¹Rheumatology, Nordic Bioscience, Herlev, Denmark, ²Biomarkers and Research, Nordic Bioscience, Herlev, Denmark
Background/Purpose: The response to any treatment in rheumatoid arthritis (RA) is assessed by symptomatic changes, such as swollen joint count and DAS28. However, such assessments…
Abstract Number: 49 • 2017 Pediatric Rheumatology Symposium
Perceptions of Methotrexate Intolerance in School-aged Children With Juvenile Idiopathic Arthritis
Charlene Hopper¹, Sarah Khan², Jacqueline Mancini² and Janet Rennick^3,4, ¹Rheumatology, Montreal Children's Hospital McGill University Health Centre, Montreal, QC, Canada, ²Ingram School of Nursing, McGill University, Montreal, QC, Canada, ³Nursing, Montreal Children's Hospital McGill University Health Centre, Montreal, QC, Canada, ⁴Ingram School of Nursing and Department of Pediatrics, McGill University, Montreal, QC, Canada
Background/Purpose: Methotrexate (MTX) remains an effective and commonly used disease modifying anti-rheumatic drug (DMARD) for the treatment of Juvenile Idiopathic Arthritis (JIA). Approximately half of the children taking MTX will…
Abstract Number: 652 • 2016 ACR/ARHP Annual Meeting
The Reasons for Discontinuation of Combination Therapy with Methotrexate and Tumor Necrosis Factor Inhibitors Versus Triple Therapy Differ Significantly Because of Higher Adverse Events with Triple Therapy
Daniel Erhardt¹, Brian C Sauer², Chia-Chen Teng², Ted R. Mikuls³, Jeffrey R. Curtis⁴ and Grant W. Cannon², ¹Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ³Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: We recently reported that real-world persistence in Veteran’s Affairs (VA) patients was lower in Rheumatoid arthritis (RA) patients receiving triple therapy [methotrexate (MTX), sulfasalazine…
Abstract Number: 2651 • 2016 ACR/ARHP Annual Meeting
Predictors of Inadequate Response and Rapid Radiographic Progression in Patients with Early Rheumatoid Arthritis Receiving Methotrexate: a Post Hoc Analysis of 2 Randomized, Controlled Trials of Adalimumab
Arthur Kavanaugh¹, Ronald F. van Vollenhoven², Benjamin A. Wolfe³, Stefan Florentinus³, Su Chen³, Jessica L. Suboticki³ and Josef S. Smolen⁴, ¹Division of Rheumatology, Allergy, and Immunology, University of California – San Diego, La Jolla, CA, ²Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, ³AbbVie Inc., North Chicago, IL, ⁴Medical University of Vienna, Vienna, Austria
Background/Purpose: Methotrexate (MTX) is recommended as first-line therapy in patients (pts) with rheumatoid arthritis (RA).1 However, information is limited regarding factors that may predict a…

« Previous Page
1
…
4
5
6
7
8
…
16
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].